FP 01 - Altimmune

Drug Profile

FP 01 - Altimmune

Alternative Names: Flunisyn; FP-01; FP-01.1

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Immune Targeting Systems
  • Developer Altimmune
  • Class Influenza A vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza A virus infections

Most Recent Events

  • 01 Sep 2015 Vaxin is now called Altimmune
  • 01 Dec 2014 Immune Targeting Systems completes a phase-I/II clinical trial in Influenza-A virus infections (prevention, in volunteers) in United Kingdom (IM) (NCT02071329)
  • 31 Jan 2014 Phase-I/II clinical trials in Influenza-A virus infections (prevention, in volunteers) in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top